Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson’s Disease

BACKGROUND: Although levodopa is considered the most effective pharmacotherapy for motor symptoms of Parkinson’s disease (PD), chronic use is associated with motor complications, including fluctuating response and unpredictable, involuntary movements called dyskinesia. ADS-5102 (amantadine) extended...

Descripción completa

Detalles Bibliográficos
Autores principales: Elmer, Lawrence W., Juncos, Jorge L., Singer, Carlos, Truong, Daniel D., Criswell, Susan R., Parashos, Sotirios, Felt, Larissa, Johnson, Reed, Patni, Rajiv
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5934466/
https://www.ncbi.nlm.nih.gov/pubmed/29532440
http://dx.doi.org/10.1007/s40263-018-0498-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5934466/
https://www.ncbi.nlm.nih.gov/pubmed/29532440
http://dx.doi.org/10.1007/s40263-018-0498-4

Ejemplares similares